162 related articles for article (PubMed ID: 36210562)
1. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies.
Moik F; Ay C
Thromb Res; 2022 May; 213 Suppl 1():S58-S65. PubMed ID: 36210562
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
3. Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies.
Moik F; Riedl JM; Englisch C; Ay C
Hamostaseologie; 2024 Feb; 44(1):40-48. PubMed ID: 38190985
[TBL] [Abstract][Full Text] [Related]
4. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy.
Goel A; Khorana A; Kartika T; Gowda S; Tao DL; Thawani R; Shatzel JJ
Eur J Haematol; 2022 Apr; 108(4):271-277. PubMed ID: 34905252
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.
Langouo Fontsa M; Aiello MM; Migliori E; Scartozzi M; Lambertini M; Willard-Gallo K; Solinas C
Target Oncol; 2022 Sep; 17(5):497-505. PubMed ID: 36102923
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions.
Prodger A; Saha P; Smith A; Evans CE
Adv Exp Med Biol; 2017; 906():115-122. PubMed ID: 27638621
[TBL] [Abstract][Full Text] [Related]
8. [Cancer and venous thromboembolism].
Meyer G; Belmont L
Rev Mal Respir; 2011 Apr; 28(4):443-52. PubMed ID: 21549900
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
10. Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis.
Trone JC; Ollier E; Chapelle C; Bertoletti L; Cucherat M; Mismetti P; Magné N; Laporte S
Ann Oncol; 2018 Apr; 29(4):803-811. PubMed ID: 29415169
[TBL] [Abstract][Full Text] [Related]
11. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
[TBL] [Abstract][Full Text] [Related]
12. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
Vigarios E; Epstein JB; Sibaud V
Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
[TBL] [Abstract][Full Text] [Related]
13. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
14. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
Drouet L
Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
[TBL] [Abstract][Full Text] [Related]
15. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis.
Grilz E; Posch F; Nopp S; Königsbrügge O; Lang IM; Klimek P; Thurner S; Pabinger I; Ay C
Eur Heart J; 2021 Jun; 42(23):2299-2307. PubMed ID: 33769475
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis associated with angiogenesis inhibitors.
Elice F; Rodeghiero F; Falanga A; Rickles FR
Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.
Posch F; Hofer S; Thaler J; Hell L; Königsbrügge O; Grilz E; Mauracher LM; Gebhart J; Marosi C; Jilma B; Pabinger I; Ay C
Transl Res; 2020 Jan; 215():41-56. PubMed ID: 31525325
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy.
Watson N; Al-Samkari H
J Thromb Haemost; 2021 Aug; 19(8):1852-1863. PubMed ID: 33928747
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
[TBL] [Abstract][Full Text] [Related]
20. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
